Myelofibrosis screening

	Myelofibrosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Myelofibrosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Myelofibrosis screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Myelofibrosis screening All Images X-rays Echo and Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Myelofibrosis screening
CDC on Myelofibrosis screening
Myelofibrosis screening in the news
Blogs on Myelofibrosis screening
Directions to Hospitals Treating Myelofibrosis
Risk calculators and risk factors for Myelofibrosis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]Sabawoon Mirwais, M.B.B.S, M.D.[3]

Overview

There is insufficient evidence to recommend routine screening for myelofibrosis and there is no screening test currently available for the disease. Routine blood work can be used to check the blood cell counts which can further warrant a bone marrow biopsy.

There is insufficient evidence to recommend routine screening for myelofibrosis.
Blood cell counts can be determined and monitored for any irregularity which can then further warrant a bone marrow biopsy.
According to 2008 World Health Organization (WHO) classification of myeloproliferative neoplasms, JAK2^V617F is the most prevalent mutation with approximately 60% of the primary myelofibrosis (PMF) patients carrying this mutation. This trend is followed in frequency by the mutations in myeloproliferative leukemia virus (MPL) and calreticulin (CALR) genes.^[1]^[2]^[3]
Patients can be screened for the above mentioned mutations based on this data.

↑ Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Guglielmelli P, Orazi A, Tefferi A (February 2018). "The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion". Blood Cancer J. 8 (2): 15. doi:10.1038/s41408-018-0054-y. PMC 5807384. PMID 29426921.
↑ Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (April 2005). "A gain-of-function mutation of JAK2 in myeloproliferative disorders". N. Engl. J. Med. 352 (17): 1779–90. doi:10.1056/NEJMoa051113. PMID 15858187.
↑ Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD (July 2009). "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes". Blood. 114 (5): 937–51. doi:10.1182/blood-2009-03-209262. PMID 19357394.